Liquid biopsy: a new source of candidate biomarkers in amyotrophic lateral sclerosis

Noninvasive tests to diagnose and monitor the progression of neurodegenerative disorders have been a challenge for decades. The aim of this study was to explore the feasibility of applying liquid biopsy procedures to patients with a neurodegenerative disease such as amyotrophic lateral sclerosis (AL...

Full description

Saved in:
Bibliographic Details
Published in:Annals of clinical and translational neurology 2018-06, Vol.5 (6), p.763-768
Main Authors: Mendioroz, Maite, Martínez‐Merino, Leyre, Blanco‐Luquin, Idoia, Urdánoz, Amaya, Roldán, Miren, Jericó, Ivonne
Format: Article
Language:English
Subjects:
Amyotrophic lateral sclerosis
Biomarkers
Brief Communication
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Noninvasive tests to diagnose and monitor the progression of neurodegenerative disorders have been a challenge for decades. The aim of this study was to explore the feasibility of applying liquid biopsy procedures to patients with a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS). We isolated plasma cell‐free DNA (cfDNA) in 20 ALS patients and 20 controls and used cfDNA to identify a novel differentially methylated mark in RHBDF2 gene in ALS patients compared to controls. Our findings support the notion that liquid biopsy may be applied to living patients as a source of potential epigenetic biomarkers for neurodegenerative disorders.
ISSN:2328-9503
2328-9503
DOI:10.1002/acn3.565